Vanguard Group’s Bristol-Myers Squibb BMY Stock Holding History

Vanguard Group’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$10.7B	Buy	198,727,768 +2,743,759	+1%	+$132M	0.16%	105
2025 Q3	$8.84B	Buy	195,984,009 +1,058,803	+0.5%	+$49.4M	0.13%	130
2025 Q2	$9.02B	Buy	194,925,206 +3,522,202	+2%	+$173M	0.15%	117
2025 Q1	$11.7B	Buy	191,403,004 +1,458,488	+0.8%	+$85M	0.21%	82
2024 Q4	$10.7B	Buy	189,944,516 +1,373,209	+0.7%	+$76.7M	0.19%	87
2024 Q3	$9.76B	Buy	188,571,307 +2,000,150	+1%	+$93.8M	0.17%	99
2024 Q2	$7.75B	Buy	186,571,157 +504,048	+0.3%	+$22.6M	0.15%	116
2024 Q1	$10.1B	Sell	186,067,109 -12,092,663	-6%	-$616M	0.2%	85
2023 Q4	$10.2B	Sell	198,159,772 -1,583,477	-0.8%	-$83.1M	0.22%	77
2023 Q3	$11.6B	Sell	199,743,249 -4,001,033	-2%	-$245M	0.28%	54
2023 Q2	$13B	Sell	203,744,282 -852,219	-0.4%	-$57.1M	0.31%	50
2023 Q1	$14.2B	Buy	204,596,501 +1,668,881	+0.8%	+$118M	0.36%	42
2022 Q4	$14.6B	Buy	202,927,620 +3,041,035	+2%	+$229M	0.4%	36
2022 Q3	$14.2B	Buy	199,886,585 +3,058,491	+2%	+$222M	0.42%	35
2022 Q2	$15.2B	Sell	196,828,094 -1,661,990	-0.8%	-$127M	0.43%	37
2022 Q1	$14.5B	Sell	198,490,084 -1,344,399	-0.7%	-$90.3M	0.34%	50
2021 Q4	$12.5B	Buy	199,834,483 +903,084	+0.5%	+$53M	0.28%	57
2021 Q3	$11.8B	Buy	198,931,399 +1,589,969	+0.8%	+$105M	0.29%	57
2021 Q2	$13.2B	Buy	197,341,430 +676,121	+0.3%	+$44.1M	0.33%	51
2021 Q1	$12.4B	Sell	196,665,309 -2,675,149	-1%	-$166M	0.34%	50
2020 Q4	$12.4B	Sell	199,340,458 -725,134	-0.4%	-$44.6M	0.36%	49
2020 Q3	$12.1B	Sell	200,065,592 -3,822,794	-2%	-$230M	0.4%	48
2020 Q2	$12B	Buy	203,888,386 +4,984,471	+3%	+$298M	0.43%	40
2020 Q1	$11.1B	Buy	198,903,915 +4,043,761	+2%	+$247M	0.47%	38
2019 Q4	$12.5B	Buy	194,860,154 +60,430,418	+45%	+$3.46B	0.43%	38
2019 Q3	$6.82B	Buy	134,429,736 +371,100	+0.3%	+$17.4M	0.25%	67
2019 Q2	$6.08B	Buy	134,058,636 +1,580,750	+1%	+$73.6M	0.23%	75
2019 Q1	$6.32B	Buy	132,477,886 +778,291	+0.6%	+$38.8M	0.25%	70
2018 Q4	$6.85B	Buy	131,699,595 +3,323,436	+3%	+$179M	0.31%	60
2018 Q3	$7.97B	Buy	128,376,159 +1,229,553	+1%	+$73M	0.31%	56
2018 Q2	$7.04B	Buy	127,146,606 +1,917,892	+2%	+$104M	0.29%	58
2018 Q1	$7.92B	Buy	125,228,714 +1,726,823	+1%	+$111M	0.35%	48
2017 Q4	$7.57B	Buy	123,501,891 +1,712,922	+1%	+$107M	0.33%	50
2017 Q3	$7.76B	Buy	121,788,969 +3,127,279	+3%	+$183M	0.36%	44
2017 Q2	$6.61B	Buy	118,661,690 +333,685	+0.3%	+$18.2M	0.33%	47
2017 Q1	$6.43B	Buy	118,328,005 +3,516,801	+3%	+$193M	0.33%	45
2016 Q4	$6.71B	Buy	114,811,204 +2,098,453	+2%	+$115M	0.37%	42
2016 Q3	$6.08B	Buy	112,712,751 +3,157,920	+3%	+$203M	0.36%	46
2016 Q2	$8.06B	Buy	109,554,831 +3,595,648	+3%	+$254M	0.5%	34
2016 Q1	$6.77B	Buy	105,959,183 +4,982,057	+5%	+$314M	0.44%	41
2015 Q4	$6.95B	Buy	100,977,126 +2,396,947	+2%	+$158M	0.47%	35
2015 Q3	$5.84B	Buy	98,580,179 +1,362,337	+1%	+$86.4M	0.42%	39
2015 Q2	$6.47B	Buy	97,217,842 +2,599,931	+3%	+$171M	0.44%	40
2015 Q1	$6.1B	Buy	94,617,911 +3,295,051	+4%	+$206M	0.41%	42
2014 Q4	$5.39B	Buy	91,322,860 +5,064,692	+6%	+$286M	0.39%	42
2014 Q3	$4.41B	Buy	86,258,168 +2,101,259	+2%	+$105M	0.34%	48
2014 Q2	$4.08B	Buy	84,156,909 +1,975,066	+2%	+$97.3M	0.32%	48
2014 Q1	$4.27B	Buy	82,181,843 +2,160,320	+3%	+$115M	0.36%	46
2013 Q4	$4.25B	Buy	80,021,523 +1,317,054	+2%	+$67.1M	0.37%	45
2013 Q3	$3.64B	Buy	78,704,469 +1,855,562	+2%	+$81.5M	0.36%	42
2013 Q2	$3.43B	Buy	+76,848,907	New	+$3.34B	0.36%	43

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group's BMY Position: Q4 2025 in Review

Vanguard Group increased its Bristol-Myers Squibb (BMY) stake by 1.4% in Q4 2025, buying an estimated $132M and bringing the position to 198,727,768 shares worth $10.7B. The position accounts for 0.16% of the portfolio, ranked #105.

Vanguard Group first reported a position in BMY in Q2 2013 and has held it in 51 quarters since. The position peaked at $15.2B in Q2 2022. 2,448 funds tracked by Wall St. Rank hold BMY as of Q4 2025.

Vanguard Group held 198,727,768 shares of Bristol-Myers Squibb worth $10.7B as of Q4 2025.
Vanguard Group bought 2,743,759 Bristol-Myers Squibb shares in Q4 2025, an estimated $132M.
Bristol-Myers Squibb made up 0.16% of Vanguard Group's portfolio in Q4 2025, its #105 holding.
Vanguard Group first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 51 quarters since.
Vanguard Group's Bristol-Myers Squibb position peaked at $15.2B in Q2 2022.
2,448 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.